Scilex Holding (SCLX) Other Non-Current Assets (2020)
Scilex Holding (SCLX) posted quarterly Other Non-Current Assets of $168973.0 for Q4 2020.
Scilex Holding (SCLX) Other Non-Current Assets (2020) Analysis & Trends
Scilex Holding (SCLX) has reported Other Non-Current Assets for 1 consecutive years, with $168973.0 the latest figure, recorded in Q4 2020.
- In Q4 2020, Other Non-Current Assets changed N/A year-over-year to $168973.0; the TTM figure through Dec 2020 stood at $168973.0 (changed N/A YoY), while the FY2020 annual figure was $168973.0, changed N/A from the prior year.
- Other Non-Current Assets came in at $168973.0 for Q4 2020 at Scilex Holding.
- The five-year high for Other Non-Current Assets was $168973.0 in Q4 2020, with the low at $168973.0 in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.23 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 14.11 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 10.54 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 19.81 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 12.76 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 4.55 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 9.83 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 200.00 Mn |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 168,973.00 |